Ryman Healthcare reports 325 sales. Ryman Healthcare stock loses 1.09 percent.

Published on 10/02/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue reached NZD 849.10 million, up 10.00 percent. Ryman Healthcare stock costs EUR 0.91 on October 2, 2026 after EUR 0.92.

RYM, NZRYME0001S4, Illustration mit AI erstellt.

Ryman Healthcare (ISIN NZRYME0001S4) reported 325 retirement living sales in the first quarter of fiscal 2027, while Ryman Healthcare stock lost 1.09 percent at Lang & Schwarz on October 2, 2026. The trading update, released on July 14, 2026, showed 265 resales and 60 new sales, according to Kapitales Research.

Resales lead fiscal 2027 activity

Net resale contracts rose 7.00 percent from the same period a year earlier, while Ryman reduced its new-sales stock by 65 units to 414 units. The mix matters because resale activity can support cash generation without the same development burden as new village inventory.

Ryman maintained fiscal 2027 delivery expectations of 157 to 168 retirement living units and aged-care beds, with completion scheduled for the second half of the fiscal year. Mature aged-care occupancy stood at 96.10 percent during the quarter, giving the sales figures an operating counterpart.

Cash flow strengthens the reset

The company entered the update with a stronger fiscal 2026 financial profile. According to Kapitales Research, operating revenue rose 10.00 percent to NZD 849.10 million in fiscal 2026.

Free cash flow reached NZD 188.30 million in fiscal 2026, compared with a NZD 94.20 million outflow in fiscal 2025. That swing gives the 325-sale update greater financial relevance, because Ryman is also working to reduce unsold stock and improve funding flexibility.

The company operates integrated retirement living and aged-care communities in New Zealand and Australia, according to its investor centre. The model combines independent living, assisted living and aged care, making occupancy and resale volumes central indicators for investors.

Stock trades below the prior close

Ryman Healthcare stock was trading at EUR 0.91 at Lang & Schwarz on October 2, 2026 at 5:05 p.m. CEST, down 1.09 percent versus the Lang & Schwarz prior close of EUR 0.92 on October 1, 2026. The NZX-listed company had a market capitalization of NZD 1.8 billion as of October 2, 2026, while its 52-week range was NZD 1.80 to NZD 3.05.